ASX RELEASE 27 October 2026 Quarterly Activities and Cashflow Report – September 2026 • Total sales for the quarter ended 30 September 2026 of US$6.3 million, up 30% on PCP • Last twelve months (LTM) sales of US$25.1 million, up 30% on the PCP, an acceleration of the growth rate compared with...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Earlier from Nova Eye Medical
- EYE lifts Sales Guidance
- EYE Delivers Sales Growth and Improves Bottom Line
- Half Yearly Report and Accounts
- Record Sales Result December 2025 Quarter
- Investor Webinar
